Epigen Biosciences

Executive Summary

Epigen Biosciences is a private, preclinical-stage biotechnology company headquartered in San Diego, focused on developing novel small-molecule therapeutics for high-unmet-need indications in neuroscience and rare diseases. Founded in 2016, the company's pipeline targets fibrotic diseases such as diabetic kidney disease, NASH/MASH, and idiopathic pulmonary fibrosis, as well as neurodegenerative disorders including Alzheimer's disease, ALS, and Fragile X Syndrome. Epigen aims to address the significant gaps in treatment options for these debilitating conditions by advancing proprietary compounds through preclinical development and toward clinical trials. While still in early stages, Epigen's diversified pipeline across multiple high-value indications offers substantial upside potential if preclinical data successfully translate into clinical benefit. The company is likely dependent on external funding or strategic partnerships to advance its programs, making near-term catalysts crucial for de-risking the platform. Given the preclinical nature and lack of disclosed specific data, the conviction remains moderate, but active progress in lead optimization or IND-enabling studies could provide meaningful milestones within the next year.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead fibrotic disease program30% success
• Q3 2026Presentation of preclinical efficacy data for Alzheimer's program at major neuroscience conference50% success
• TBDAnnouncement of strategic partnership or licensing deal for NASH/MASH program20% success